scholarly journals A case of pheochromocytoma of the urinary bladder and renal cell carcinoma in a long-term hemodialysis patient

2009 ◽  
Vol 42 (8) ◽  
pp. 595-599
Author(s):  
Yasuto Yamasaki ◽  
Junichi Watanabe ◽  
Naofumi Sakimura ◽  
Kenichi Miyazaki ◽  
Yoshiaki Muraya ◽  
...  
BMC Urology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mustufa Babar ◽  
Saad Hamdani ◽  
Corinne Liu ◽  
Jogarao Vedula ◽  
David S. Schnapp

Abstract Background Metachronous renal cell carcinoma after radical nephrectomy is extremely rare. Renal cell carcinoma commonly metastasizes to distant organs. However, metastasis to the urinary bladder is very uncommon. Case presentation Herein, we report a case of metachronous renal cell carcinoma with metastasis to the urinary bladder, left acetabulum, left rib, lungs, thyroid, right renal vein and inferior vena cava. The patient had undergone a left-sided radical nephrectomy 28 years ago. The pathological diagnosis of a fragment of the bladder tumor was consistent with Fuhrman grade 2 clear cell renal cell carcinoma. Conclusions Although metachronous renal cell carcinoma after radical nephrectomy is rare, active surveillance should be still considered. Renal cell carcinoma has shown to unusually metastasize to the urinary bladder, a rarely reported organ of metastasis. Treatment options, such as immunotherapy, are available to patients with such metastasis and long-term survivorship can be achieved.


2007 ◽  
Vol 21 (4) ◽  
pp. 239-243 ◽  
Author(s):  
Nozomi Ozawa ◽  
Terue Okamura ◽  
Koichi Koyama ◽  
Yoshimasa Hamazawa ◽  
Hideto Senzaki ◽  
...  

2001 ◽  
Vol 92 (1) ◽  
pp. 42-46
Author(s):  
Masayuki Tokumitsu ◽  
Fumie Inada ◽  
Noriaki Masui ◽  
Hironori Ishida ◽  
Hatuichi Ishida ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 355-355
Author(s):  
Manuel Eisenberg ◽  
John S. Lam ◽  
Rakhee H. Goel ◽  
Allan J. Pantuck ◽  
Robert A. Figlin ◽  
...  

2021 ◽  
Vol 69 (4) ◽  
pp. 888-892
Author(s):  
Joseph I Clark ◽  
Brendan Curti ◽  
Elizabeth J Davis ◽  
Howard Kaufman ◽  
Asim Amin ◽  
...  

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival compared with patients who progress, but limited data are available describing the long-term course. The aim of this study was to better characterize long-term survival following successful HD IL-2 treatment in patients with no subsequent systemic therapy. Eleven HD IL-2 treatment centers identified patients with survival ≥5 years after HD IL-2, with no subsequent systemic therapy. Survival was evaluated from the date of IL-2 treatment to June 2017. Treatment courses consisted of 2 1-week cycles of HD IL-2. Patients were treated with HD IL-2 alone, or HD IL-2 followed by local therapy to achieve maximal response. 100 patients are reported: 54 patients with mM and 46 patients with mRCC. Progression-free survival (PFS) after HD IL-2 ranges from 5+ years to 30+ years, with a median follow-up of 10+ years. 27 mRCC and 32 mM are alive ≥10 years after IL-2. Thus, a small subset of patients with mM and mRCC achieve long-term PFS (≥5 years) after treatment with HD IL-2 as their only systemic therapy. The ability of HD IL-2 therapy to induce prolonged PFS should be a major consideration in studies of new immunotherapy combinations for mM and mRCC.


Sign in / Sign up

Export Citation Format

Share Document